alphakinase 500000 iu ly.pd.inj
kite ΕΛΛΑΣ ΕΠΕ - ΕΝΕΣΙΜΟ ΛΥΟΦΙΛΟ - 500000 iu
alphosyl conditioning shampoo 5% w/v med.shamp
kite ΕΛΛΑΣ ΕΠΕ - ΣΑΠΩΝ ΓΙΑ ΤΟ ΤΡΙΧΩΤΟ ΤΗΣ ΚΕΦΑΛΗΣ (ΣΑΜΠΟΥΑΝ) - 5% w/v
arutidor (20+5)mg/ml ey.dro.sol
kite ΕΛΛΑΣ ΕΠΕ - timolol, combinations - ΟΦΘΑΛΜΙΚΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ - (20+5)mg/ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
otomize 195iu+(0,06+1,2)mg/dose ωτικο εκνεφωμα, γαλακτωμα
kite ΕΛΛΑΣ ΕΠΕ (0000001277) Λεωφ. Ιωνίας 166,, 111 44, ΑΘΗΝΑ, 111 44 - neomycin sulfate; dexamethasone; acetic acid - ΩΤΙΚΟ ΕΚΝΕΦΩΜΑ, ΓΑΛΑΚΤΩΜΑ - 195iu+(0,06+1,2)mg/dose - 0001405103 neomycin sulfate 195.000000 iu; 0000050022 dexamethasone 0.060000 mg; 0000064197 acetic acid 1.200000 mg - dexamethasone and antiinfectives
quadrasa 2g/flacon rec.sol
kite ΕΛΛΑΣ ΕΠΕ - ΟΡΘΙΚΟ ΔΙΑΛΥΜΑ - 2g/flacon
vividrin 2% (w/v) ey.sol.sd
kite ΕΛΛΑΣ ΕΠΕ - cromoglicic acid - ΚΟΛΛΥΡΙΟ ΔΙΑΛΥΜΑ ΜΙΑΣ ΔΟΣΗΣ - 2% (w/v) - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
selsun 2,5% med.shamp
kite ΕΛΛΑΣ ΕΠΕ - selenium compounds - ΣΑΠΩΝ ΓΙΑ ΤΟ ΤΡΙΧΩΤΟ ΤΗΣ ΚΕΦΑΛΗΣ (ΣΑΜΠΟΥΑΝ) - 2,5% - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - Λέμφωμα, mantle-cell - Αντινεοπλασματικοί παράγοντες - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
tecartus disp.inf 0.4 - 2 x 10 8 κύτταρα
kite pharma eu b.v., the netherlands tufsteen 1, 2132 nt hoofddorp - autologous anti-cd19-transduced cd3+ cells - disp.inf (ΔΙΑΣΠΟΡΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 0.4 - 2 x 10 8 κύτταρα - autologous anti-cd19-transduced cd3+ cells 0,4ce - other antineoplastic agents